The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis

Liver International

Volumn 30, Issue 6, 2010, Pages 795-808

  Schuppan, Detlef ^a   Gorrell, Mark D ^b   Klein, Thomas ^c   Mark, Michael ^c   Afdhal, Nezam H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Angiotensin receptor; Antagonist; Antifibrotic therapy; Biopsy; Cirrhosis; Collagen; DPP 4; Elastography; Fatty liver; Fibroscan; Fibrosis; Fibrosis marker; Metabolic syndrome; NAFLD; NASH; Renin angiotensin system; Serum marker; Steatohepatitis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ALPHA TOCOPHEROL; ALPHAVBETA6 INTEGRIN; ANGIOTENSIN 1 RECEPTOR; CYTOKERATIN 18; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EOTAXIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; LINAGLIPTIN; METFORMIN; NEUROPEPTIDE Y; PEPTIDE YY; PIOGLITAZONE; PROCOLLAGEN; PROLACTIN; ROSIGLITAZONE; SUBSTANCE P; SUPERPARAMAGNETIC IRON OXIDE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; COLLAGEN METABOLISM; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE MODEL; DRUG RESEARCH; ECHOGRAPHY; EXERCISE; FIBROGENESIS; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CHEMISTRY; COMPLICATION; CONSENSUS DEVELOPMENT; DRUG DESIGN; DRUG EFFECTS; FATTY LIVER; LIVER CIRRHOSIS; PREDICTIVE VALUE; RISK REDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DRUG DESIGN; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; RENIN-ANGIOTENSIN SYSTEM; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77954375834     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02264.x     Document Type: Review

References (119)

1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40((Suppl. 1)):S5-10.
2. Ludwig J, Viggiano TR, McGill DB. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-8.
3. Grattagliano I, Portincasa P, Palmieri VO. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician 2007, 53:857-63.
4. Hultcrantz R, Glaumann H, Lindberg G. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986, 21:109-13.
5. Ground KE. Liver pathology in aircrew. Aviat Space Environ Med 1982, 53:14-8.
6. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-7.
7. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 2008, 115:141-50.
8. Powell EE, Cooksley WG, Hanson R. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
9. Hui JM, Kench JG, Chitturi S. Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38:420-7.
10. Adams LA, Lymp JF, St Sauver J. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-21.
11. Kawada N, Imanaka K, Kawaguchi T. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009, 44:1190-4.
12. Browning JD, Szczepaniak LS, Dobbins R. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-95.
13. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009, 8((Suppl. 1)):S4-8.
14. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007, 11:1-16.
15. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50:204-10.
16. Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr Drug Discov Technol 2007, 4:133-40.
17. Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-906.
18. Merriman RB, Ferrell LD, Patti MG. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44:874-80.
19. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 2002, 294:1-4.
20. Macías-Rodríguez RU, Torre A. Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview. Rev Invest Clin 2009, 61:161-72.
21. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009, 9:299-314.
22. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81.
23. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008, 371:838-51.
24. Moore AF, Jablonski KA, McAteer JB. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 2008, 57:2503-10.
25. Romeo S, Kozlitina J, Xing C. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-5.
26. Wagenknecht LE, Scherzinger AL, Stamm ER. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring) 2009, 17:1240-6.
27. Schwimmer JB, Celedon MA, Lavine JE. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-92.
28. Nishimura S, Manabe I, Nagasaki M. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-20.
29. Winer S, Chan Y, Paltser G. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009, 15:921-9.
30. Feuerer M, Herrero L, Cipolletta D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-9.
31. Popov Y, Schuppan D. CD8+ T cells drive adipose tissue inflammation - a novel clue for NASH pathogenesis? J Hepatology 2010, 52:130-2.
32. Day CP, James OF. Steatohepatitis: a tale of two " hits" ? Gastroenterology 1998, 114:842-5.
33. London RM, George J. Pathogenesis of NASH: animal models. Clin Liver Dis 2007, 11:55-74.
34. Puri P, Wiest MM, Cheung O. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 51:1827-38.
35. Feldstein AE, Canbay A, Angulo P. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-43.
36. Richardson MM, Jonsson JR, Powell EE. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007, 133:80-90.
37. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Sem Liver Dis 2008, 28:370-9.
38. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-69.
39. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009, 50:1294-306.
40. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001, 54:249-64.
41. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J 2003, 373:179-89.
42. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004, 1679:18-28.
43. Chen T, Ajami K, McCaughan GW. Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. Biochim Biophys Acta 2006, 1764:33-43.
44. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005, 108:277-92.
45. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology 2005, 42:935-45.
46. Balaban YH, Korkusuz P, Simsek H. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007, 6:242-50.
47. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994, 15:180-4.
48. Löster K, Zeilinger K, Schuppan D, Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 1995, 217:341-8.
49. Yang J, Campitelli J, Hu G. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007, 81:272-9.
50. Lakatos PL, Firneisz G, Borcsiczky D. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur J Clin Invest 2000, 30:793-7.
51. Itou M, Kawaguchi T, Taniguchi E. Altered expression of glucagon-like peptide and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol 2008, 23:244-51.
52. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2009, 118:31-41.
53. Liu Z, Christensson M, Forslow A, De Meester I, Sundqvist K-G. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009, 183:3616-24.
54. Marzioni M, Alpini G, Saccomanno S. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009, 58:990-7.
55. Richter B, Bandeira-Echtler E, Bergerhoff K. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-68.
56. Yilmaz Y, Atug O, Yonal O. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med Sci Monit 2009, 15:1-5.
57. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-81.
58. Pocai A, Carrington PE, Adams JR. Glucagon-like peptide 1/glucagon receptor dual agonsim dual agonism reverses obesity in mice. Diabetes 2009, 58:2258-66.
59. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008, 48:1171-8.
60. Heise T, Graefe-Mody EU, Hüttner S. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-94.
61. Ribeiro-Oliveira A, Nogueira AI, Pereira RM. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 2008, 4:787-803.
62. Yang L, Bataller R, Dulyx J. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005, 43:317-23.
63. Costa FV. Telmisartan: standing out in a crowded contest? High Blood Press Cardiovasc Prev 2006, 13:85-94.
64. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun 2007, 364:801-7.
65. Kudo H, Yata Y, Takahara T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liv Int 2009, 29:988-96.
66. Fujita K, Yoneda M, Wada K. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007, 52:3455-64.
67. Fallowfield JA, Mizuno M, Kendall TJ. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007, 178:5288-95.
68. Nagarajan P, Venkatesan R, Kumar M. Macaca radiata (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease. Liver Int 2008, 28:856-64.
69. Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in non-alcoholic steatohepatitis. Liver Int 2008, 28:650-8.
70. Wieckowska A, Zein NN, Yerian LM. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
71. Diab DL, Yerian L, Schauer P. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008, 6:1249-54.
72. Feldstein AE, Wieckowska A, Lopez AR. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-8.
73. Malik R, Chang M, Bhaskar K. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009, 24:564-8.
74. Younossi ZM, Jarrar M, Nugent C. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-7.
75. Naganawa S, Kawai H, Fukatsu H. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005, 4:175-186.
76. Aube C, Racineux PX, Lebigot J. Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results. J Radiol 2004, 85:301-6.
77. Girometti R, Furlan A, Bazzocchi M. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med 2007, 112:394-408.
78. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005, 22:80-5.
79. Elizondo G, Weissleder R, Stark DD. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990, 174:797-801.
80. Lucidarme O, Baleston F, Cadi M. Non-invasive detection of liver fibrosis: is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003, 13:467-74.
81. Yamashita Y, Yamamoto H, Hirai A. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: influence of liver dysfunction and parenchymal pathology. Abdom Imaging 1996, 21:318-23.
82. Aguirre DA, Behling CA, Alpert E. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006, 239:425-37.
83. Patsenker E, Popov Y, Stickel F. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660-70.
84. Popov Y, Patsenker E, Stickel F. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008, 48:453-64.
85. Friedrich-Rust M, Ong MF, Martens S. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-74.
86. Talwalkar JA, Yin M, Fidler JL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008, 47:332-42.
87. Huwart L, Sempoux C, Vicaut E. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
88. Schuppan D, Popov Y. Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 2009, 33:949-57.
89. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-62.
90. De Ledinghen V, Beaugrand M, Kelleher TB. Prediction of liver fibrosis in non alcoholic steatohepatitis (NASH): risk factors and diagnostic potential of liver elasticity using FibroScan. J Hepatol 2006, 44((Suppl. 2)):S39.
91. Foucher J, Chanteloup E, Vergniol J. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006, 55:403-8.
92. Shackel NA, Seth D, Haber PS, Gorrell MD, McCaughan GW. The hepatic transcriptome in human liver disease. Comp Hepatol 2006, 5:6-16.
93. Weber S, Gressner OA, Hall R. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin Liver Dis 2008, 12:747-57.
94. McHutchison J, Poynard T, Afdhal N. International fibrosis group meeting participants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006, 4:1214-20.
95. Kleinert DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-21.
96. Yoneda M, Endo H, Nozaki Y. Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci 2007, 105:151-6.
97. Caldwell SH, Hespenheide EE, Redick JA. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519-25.
98. Ratziu V, Giral P, Jacqueminet S. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008, 135:100-10.
99. Aithal GP, Thomas JA, Kaye PV. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-84.
100. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-307.
101. Marchesini G, Brizi M, Bianchi G. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-4.
102. Lindor KD, Kowdley KV, Heathcote EJ. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-8.
103. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-17.
104. Promrat K, Lutchman G, Uwaifo GI. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-96.
105. Dufour JF, Oneta CM, Gonvers JJ. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-43.
106. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734-8.
107. Sanyal AJ, Mofrad PS, Contos MJ. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107-15.
108. Hasegawa T, Yoneda M, Nakamura K. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667-72.
109. Kugelmas M, Hill DB, Vivian B. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-9.
110. Harrison SA, Torgerson S, Hayashi P. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-90.
111. Ota T, Takamura T, Kurita S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007, 132:282-93.
112. Nakayama H, Otabe S, Ueno T. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to non-alcoholic steatohepatitis. Metabolism 2007, 56:470-5.
113. Lee SJ, Heinrich G, Fedorova L. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008, 135:2084-95.
114. Kong B, Luyendyk JP, Tawfik O. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009, 328:116-22.
115. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008, 36:146-64.
116. Matsuzawa N, Takamura T, Kurita S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-403.
117. Baumgardner JN, Shankar K, Hennings L. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 2008, 294:G27-38.
118. Cong WN, Tao RY, Tian JY. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 2008, 82:983-90.
119. de Lima VM, Oliveira CP, Alves VA. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol 2008, 49:1055-61.